BOCA RATON, Fla., Oct. 19 /PRNewswire-FirstCall/ -- Stem Cell Assurance, Inc. (Pink Sheets: SCLZ) announced today the appointment of Mark Weinreb as Chief Executive Officer and as a member of the Company's Board of Directors. Mr. Weinreb is a well-recognized and respected professional within the medical and financial communities.
Mr. Weinreb offers expertise in public (President and CEO of AMEX and NASDAQ listed companies) and private corporate management, in the areas of healthcare, medical devices, research programs, franchising, and business/product development. Mr. Weinreb was most recently President and a director of NeoStem, Inc., a public biotechnology medical services company specializing in enhancing the delivery of adult stem cell therapeutics and developing an international network of adult stem cell collection centers.
Mr. Weinreb also was an owner and operator of BioHealth Laboratories, Inc., a leading diagnostic state-of-the-art medical laboratory providing clinical testing services for physicians, hospitals, and other medical laboratories. He was educated at Northwestern University and C.W. Post (Long Island University).
Gloria McConnell, President of Stem Cell Assurance, stated, "We are extremely pleased and fortunate to have a seasoned entrepreneur and executive of Mr. Weinreb's caliber become so excited about our Company that he has accepted our offer to become our full time chief executive officer and provide his leadership skills in growing the Company's business."
Said Mr. Weinreb, "I believe the Company's business has tremendous potential, and I very much look forward to embarking on an aggressive growth strategy that will position the Company to capitalize on current and future therapeutic uses of adult stem cells."
About Stem Cell Assurance, Inc.
Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications. The Company intends to offer, through its "Lipo Rejuvenation Centers," the collection of adipose tissue for use in cosmetic treatments and for the separation and storage of adult stem cells. The Company also operates a wholly-owned subsidiary, Stem Cellutrition™, which offers and sells facial creams and products.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
SOURCE Stem Cell Assurance, Inc.